Efgartigimod is an investigational drug that is being developed by a company called argenx. Efgartigimod is thought to reduce autoimmune antibodies that contribute to neuromuscular weakness in gMG. During the ADAPT study, efgartigimod or a placebo is given by a healthcare professional through intravenous (IV) infusion over a period of one hour to evaluate the efficacy and safety of the investigational drug.
If you are over 18 and have a diagnosis of generalized MG, you may be eligible to participate in this study.
This website requires cookies to provide all of its features and uses tracking technologies. For more information, please see the Website Usage Policies page. If you continue to use this site, you agree with the Terms and Conditions.Learn More